Ignite Creation Date:
2024-05-05 @ 11:19 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00003900
Status:
COMPLETED
Last Update Posted:
2016-07-06
First Post:
1999-11-01
Brief Title:
Irinotecan With Docetaxel in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer
Sponsor:
Alliance for Clinical Trials in Oncology
Organization:
Alliance for Clinical Trials in Oncology
Study Overview
Official Title:
A Phase II Study of Irinotecan CPT-11 and Docetaxel Taxotere in Patients With Recurrent Non-Small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2016-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die Combining more than one drug may kill more tumor cells
PURPOSE Phase II trial to study the effectiveness of combining irinotecan and docetaxel in treating patients who have recurrent or metastatic non-small cell lung cancer
PURPOSE Phase II trial to study the effectiveness of combining irinotecan and docetaxel in treating patients who have recurrent or metastatic non-small cell lung cancer
Detailed Description:
OBJECTIVES I Evaluate the response rate of previously treated patients with recurrent non-small cell lung cancer after treatment with irinotecan and docetaxel II Determine the toxicity of this regimen in these patients III Determine the overall survival in this patient population
OUTLINE Patients receive irinotecan IV over 90 minutes immediately followed by docetaxel IV over 60 minutes on day 1 Treatment is repeated every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity Patients are followed every 3 months for 5 years or until death
OUTLINE Patients receive irinotecan IV over 90 minutes immediately followed by docetaxel IV over 60 minutes on day 1 Treatment is repeated every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity Patients are followed every 3 months for 5 years or until death
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CDR0000067071 | REGISTRY | PDQ Physician Data Query | None |